Liangliang Xu (LiangLiang Xu)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 10

Top Venues

Phytotherapy research : PTR

BioMed research international

Stem cell research & therapy

Oxidative medicine and cellular longevity

Chinese University of Hong Kong (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Chinese University of Hong Kong

Hong Kong

PHD

Publications

Min Wang, Zhao Gao, Yage Zhang, Qiangqiang Zhao, Xinfang Tan, Siluo Wu, Lingli Ding, Yamei Liu, Shengnan Qin, Jiangyong Gu, Liangliang Xu
Syringic acid promotes cartilage extracellular matrix generation and attenuates osteoarthritic cartilage degradation by activating TGF-β/Smad and inhibiting NF-κB signaling pathway. Phytotherapy research : PTR 38 (2) (2023)
Min Wang, Zhao Gao, Yage Zhang, Qiangqiang Zhao, Xinfang Tan, Siluo Wu, Lingli Ding, Yamei Liu, Shengnan Qin, Jiangyong Gu, Liangliang Xu
Syringic acid promotes cartilage extracellular matrix generation and attenuates osteoarthritic cartilage degradation by activating TGF-β/Smad and inhibiting NF-κB signaling pathway. Phytotherapy research : PTR 38 (2) (2023)
Min Wang, Zhao Gao, Yage Zhang, Qiangqiang Zhao, Xinfang Tan, Siluo Wu, Lingli Ding, Yamei Liu, Shengnan Qin, Jiangyong Gu, Liangliang Xu
Syringic acid promotes cartilage extracellular matrix generation and attenuates osteoarthritic cartilage degradation by activating TGF-β/Smad and inhibiting NF-κB signaling pathway. Phytotherapy research : PTR (2023)
Lingli Ding, Zhao Gao, Siluo Wu, Chen Chen, Yamei Liu, Min Wang, Yage Zhang, Ling Li, Hong Zou, Guoping Zhao, Shengnan Qin, Liangliang Xu
Ginsenoside compound-K attenuates OVX-induced osteoporosis via the suppression of RANKL-induced osteoclastogenesis and oxidative stress. Natural products and bioprospecting 13 (1) (2023)
Puiian Wong, Zheng Lv, Jinglan Li, Qiushi Wei, Liangliang Xu, Bin Fang, Yiwen Luo, Min-Cong He
A Novel RANKL-Targeted Furoquinoline Alkaloid Ameliorates Bone Loss in Ovariectomized Osteoporosis through Inhibiting the NF- κ B Signal Pathway and Reducing Reactive Oxygen Species. Oxidative medicine and cellular longevity 2022 (2022)
Yonghui Hou, Bingyu Zhou, Ming Ni, Min Wang, Lingli Ding, Ying Li, Yamei Liu, Wencai Zhang, Gang Li, Jiali Wang, Liangliang Xu
Nonwoven-based gelatin/polycaprolactone membrane loaded with ERK inhibitor U0126 for treatment of tendon defects. Stem cell research & therapy 13 (1) (2022)
Jiaqian Zheng, Yanni Huang, Ying Li, Jieqing Lai, Chen Chen, Chunzhi Yi, Fengxiang Pang, Yun Lan, Liangliang Xu, Bin Fang
lncRNA-TINCR Functions as a Competitive Endogenous RNA to Regulate the Migration of Mesenchymal Stem Cells by Sponging miR-761. BioMed research international 2020 (2020)
Weiping Lin, Linfeng Huang, Ying Li, Bin Fang, Gang Li, Leilei Chen, Liangliang Xu
Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities. BioMed research international 2019 (2019)
Bin Fang, Ding Wang, Jiaqian Zheng, Qiushi Wei, Dongxiang Zhan, Yamei Liu, Xuesong Yang, Haibin Wang, Gang Li, Wei He, Liangliang Xu
Involvement of tumor necrosis factor alpha in steroid-associated osteonecrosis of the femoral head: friend or foe? Stem cell research & therapy 10 (1) (2019)
Yanming Cao, Bin Wang, Ding Wang, Dongxiang Zhan, Caiyuan Mai, Peng Wang, Qiushi Wei, Yamei Liu, Haibin Wang, Wei He, Liangliang Xu
Expression of Sclerostin in Osteoporotic Fracture Patients Is Associated with DNA Methylation in the CpG Island of the SOST Gene. International journal of genomics 2019 (2019)

Liangliang Xu.css-eqlu8i{font-size:small;padding-left:4px;} (LiangLiang Xu)

Publication Activity (10 Years)

Top Topics

Top Venues

Liangliang Xu (LiangLiang Xu)